BAA-065
BAA-065 is a selective and orally active PKMYT1 inhibitor with an IC50 of <50 nM. BAA-065 inhibits cancer cells proliferation, induces γH2AX expression and DNA damage. BAA-065 inhibits tumor growth in OVCAR3 xenograft mice. BAA-065 can be used for the research of cancer, such as ovarian cancer.
For research use only. We do not sell to patients.
- Formula: C25H31N5O4S
- Molecular Weight:497.61
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
|
PKMYT1 <50 nM (IC50) |
BAA-065 (6-500 nM) selectively induces γH2AX expression in multiple sensitive cancer cell lines, modulates cellular biomarkers of cell cycle progression and DNA damage in combination with topoisomerase 1 inhibitor SN38 (HY-13704) in OVCAR3 cells, and affects biomarkers of cell cycle progression in HCC1596 breast cancer cell line[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Human ovarian cancer OVCAR3 xenograft mice models[1]
-
Dosage:160 mg/kg
-
Administration:p.o.; qd for 18 days
-
Result:Inhibited tumor growth.
Showed stronger antitumor activity combined with antibody-drug conjugate bearing topoisomerase 1 inhibitor payload.
Chemical Information
-
Molecular Weight 497.61
-
Formula C25H31N5O4S
-
SMILES
O=C(C1=CN=C(NC2=NC(C(NC(C)(C)C)=O)=CC=C2OC(C)C)S1)NC3=C(C)C=CC(O)=C3C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)